The investigational compound OGX-427 is designed to inhibit the production of the heat shock protein 27 (hsp27), a cell survival protein expressed in many types of cancers including prostate, bladder, breast and non-small cell lung cancer. Researchers at the BC Cancer Agency report hsp27 is thought to be an important factor leading to the development of treatment resistance and is associated with negative clinical outcomes in patients with various types of tumors.
The aim of the phase II multicenter randomized prostate cancer study (see poster # 121) was to evaluate patients without disease progression at the 12-week mark after treatment with prednisone given with or without OGX-427. The study also assessed the proportion of patients who had a PSA decline and measurable disease response.
In the OGX-427 plus prednisone arm, 71% of the patients were progression-free at 12 weeks compared to 33% in the prednisone arm alone. Similarly, 76% of the OXG-427 patient cohort experienced an overall decline in the PSA. “Response rates observed thus far are supportive of OGX-427’s ability to suppress androgen receptor activity and tumor cell survival through inhibition of hsp27,” according to Kim N. Chi, MD, and primary investigator of the prostate cancer study.
Presented by Kim N. Chi, MD,1 et al, at the 2012 Genitourinary Cancers Symposium - February 2 - 4, 2012 - San Francisco Marriott Marquis - San Francisco, California
1BC Cancer Agency Research Centre, Vancouver, British Columbia
Related Item:
View Full 2012 GU Cancers Symposium Coverage
